REHAB RADAR | Global Brief: With regulatory easing worldwide and a surge in capital acquisitions, will industry development accelerate?

Regulatory policies across multiple countries are moving toward greater coordination and simplification, while cutting-edge technologies such as AI and brain-computer interfaces are accelerating their commercialization, jointly driving faster industrial innovation and market access.

On February 1, Malaysia and Thailand officially launched a three-month pilot program for mutual recognition of medical device regulation, marking a substantive step forward in regulatory harmonization across Southeast Asia. The initiative focuses on Class B, C, and D medical devices—those classified as medium- to high-risk—with the core objective of establishing a trust‑based mechanism to reduce redundant reviews and assessments, thereby significantly lowering compliance costs and accelerating time-to-market for manufacturers. Under the pilot, Malaysia has shortened the review timeframe for devices approved by the TFDA to 30 working days. The overall processing cycle has been shortened by 50%; in Thailand, external expert reviews have been waived, the review period has been reduced to 120 calendar days, and expert review fees are exempted.

Mexico has issued a decree enacting sweeping reforms to the General Health Law. As Latin America’s second-largest medical device market, this legislative overhaul sends a significant signal: first, it signals a new direction for government procurement, with the new law stipulating that, in centralized purchasing procedures, the Ministry of Health will promote a priority‑based mechanism. Prioritize enterprises that have invested in production chains and built factories within Mexico, as well as those that procure innovative products. , which will take effect starting in fiscal year 2026 and be implemented upon the delivery of products in 2027; second, in the area of infrastructure and high‑tech equipment, the new law establishes the “National Health Infrastructure and High‑Tech Medical Equipment Master Plan,” Public institutions must obtain a registration number when constructing new facilities or acquiring high‑tech equipment; otherwise, they will be ineligible for funding or procurement approval, leading to longer sales cycles. Enterprises are required to assist hospitals in conducting thorough preliminary needs assessments.

Singapore’s and Indonesia’s pharmaceutical regulatory authorities recently signed a comprehensive memorandum of understanding, elevating bilateral cooperation to a new level. The scope of cooperation extends beyond… Joint review of pharmaceuticals and health products, coordinated oversight of clinical trials, and shared post‑marketing safety monitoring. , more proactively incorporated Joint exploration of cutting-edge fields such as advanced therapeutic products and the application of artificial intelligence in regulatory science. Both parties hold regulatory qualifications recognized by the World Health Organization, laying a solid foundation for this in-depth collaboration.

In its recently issued guidance, the U.S. Food and Drug Administration (FDA) has articulated a more lenient regulatory stance toward low‑risk, general‑health products. The new policy clearly delineates the boundary between consumer‑grade health products and medical devices: for products primarily intended to promote healthy lifestyles, non‑invasive, and posing very low risk—such as the fitness‑tracking features of standard smartwatches—the FDA will no longer subject them to mandatory premarket review as medical devices. This adjustment aims to foster innovation in the digital health sector and lower compliance barriers for start‑ups. However, the FDA also stresses that products with diagnostic or therapeutic functions for specific conditions will continue to be governed by stringent regulatory standards.

Sunrise Medical, a global leader in assistive mobility solutions, announced the completion of its acquisition of Ergoflix, a leading German manufacturer of high-end folding electric wheelchairs. This acquisition will strengthen Sunrise Medical’s portfolio of premium standard rehabilitation products while complementing its existing complex rehabilitation business. Both companies stated that this move aligns with demographic trends, addresses growing consumer demand for independent living at home, and plans to expand Ergoflix’s distributor‑based business model into international markets.

Elon Musk’s brain-computer interface company, Neuralink, has achieved two groundbreaking advances. First, Neuralink’s first human subject has had their brain-computer interface upgraded wirelessly over the air—much like a Tesla vehicle receives OTA updates. , it is possible to fix brain‑module “bugs” and enhance performance without surgery—marking the first time in human history that the brain can be infinitely iterated, much like a smartphone or an automotive system. Second, Neuralink announced that, It is planned to launch mass production of brain-computer interface devices in 2026. Together, these two advances mark a crucial step forward in moving brain–computer interface technology from clinical trials toward potential mass-market products.

U.S.-based digital physical therapy company Sword Health has acquired its competitor Kaia Health for $285 million, paving the way for expansion in Europe. The acquisition aims to integrate both companies’… Technologies and Resources in the Field of Digital Musculoskeletal (MSK) Care By eliminating competition and consolidating its user base, Sword Health has not only solidified its dominant position in the U.S. market but has also positioned itself for further expansion into the European market.

German health-tech company Voize has successfully closed a $50 million Series A funding round. The company focuses on developing applications for… AI-Driven Voice Assistant for Professional Nursing and Clinical Settings , aiming to streamline workflows such as nursing documentation and information retrieval through natural language interaction, thereby enhancing healthcare efficiency. This round of funding was led by a prominent venture capital firm, with participation from existing investors. The proceeds will be primarily used to accelerate the penetration of its solutions in Europe’s established markets and to officially launch its expansion into the U.S. market.

Source: REHACARE Rehabilitation Exhibition